ZTe | heterocyclic compounds d-out qh |
BT | +ZDe organic compounds qh ah |
ZT2 | heterocyclic acid qh |
NT | +ZP18.4e nicotinic acid qh ah | |
ZQ8.2e meperidine qh ah | ||
+ZT6.10.4e indoleacetic acid qh ah |
ZT2.2 | . isonipecotic acid qh |
BT | +ZT4.20e piperidine qh ah |
ZT2.4 | . nipecotic acid qh |
ZT4 | 1-ring heterocyclic compounds qh |
ZT4.2e | . azepine qh |
ZT4.2.2e | . . pentylenetetrazole qh |
BT | +YW8.6 convulsants qh ah |
ZT4.4e | . azocine qh |
ZT4.4.2e | . . cyclazocine qh |
ZT4.6e | . azole qh |
ZT4.6.2e | . . tetrazole qh |
ZT4.6.2.2e | . . . tetrazolium salt qh |
ZT4.6.4e | . . chlormethiazole qh |
ST | clomethiazole | |
BT | +YP4.6e alcohol withdrawal agents qh ah |
ZT4.6.6e | . . atipamezole qh |
BT | +YP4.2e anti-alcohol-intoxication agents qh ah |
ZT4.6.8e | . . nitrefazole qh |
ST | 2-methyl-4-nitro-1-(4-nitrophenyl) imidazole | |
BT | +YP4.8.8e alcohol deterrents qh ah |
ZT4.8e | . dioxin qh |
ZT4.8.2e | . . tetrachlorodibenzodioxin qh |
ZT4.10 | . fentanyl qh |
BT | +BT6.4.10.2 schedule II opiates qh ah | |
+YW4.2e narcotic analgesics qh ah | ||
+ZQ8 phenylpiperidine derivative opioids qh ah | ||
+ZQ18e synthetic opioids qh ah |
ZT4.12e | . furan qh |
ZT4.12.2e | . . nitrofuran qh |
BT | +YT12.2 urinary anti-infective agents qh ah |
ZT4.12.2.2e | . . . furazolidone qh |
BT | +YD8.2 ADH antagonists qh ah |
ZT4.12.2.4e | . . . nitrofurantoin qh |
ZT4.12.4e | . . ranitidine qh |
BT | +YT10.8 antiulcer agents qh ah | |
+YT10.14 antisecretory agents qh ah | ||
+YV6.4.4e histamine H2 receptor blockaders qh ah |
ZT4.14e | . imidazoles qh |
ZT4.14.2e | . . clonidine qh |
SN | Originally developed as an antihypertensive medicine, clonidine has been found to be an effective nonopiate drug for controlling withdrawal from opiates and opioids. Subjects experience only mild discomfort detoxifying with clonidine, and its use has been proposed as a transition drug to bridge the gap in moving addicts from methadone treatment to antagonist (e.g., naltrexone) treatment. | |
BT | +YP4.6e alcohol withdrawal agents qh ah | |
+YP4.8.12.8 agents for alcohol-concurrent anxiety qh ah | ||
+YP4.8.12.10 agents for alcohol-related cognitive impairment qh ah | ||
+YP8 anti-nicotine-abuse agents qh ah | ||
+YP12.4 opiate detoxification agents qh ah | ||
+YP12.6 opiate withdrawal agents qh ah | ||
+YT8.8 antihypertensive agents qh ah |
ZT4.14.4e | . . creatinine qh |
RT | HF2e urinalysis qh ah |
ZT4.14.6e | . . hydantoin qh |
BT | +YW4.6e anticonvulsants qh ah |
ZT4.14.6.2e | . . . phenytoin qh |
BT | +YP4.6.12 anti-alcohol-related-seizures agents qh ah | |
+YT8.2 antiarrhythmia agents qh ah |
ZT4.14.6.4e | . . . thiohydantoin qh |
ZT4.14.6.4.2e | . . . . phenylthiohydantoin qh |
ZT4.14.8e | . . nitroimidazole qh |
ZT4.14.8.2e | . . . metronidazole qh |
BT | +YD8.2 ADH antagonists qh ah |
ZT4.14.10 | . . ondansetron qh |
BT | +YP4.8.2.8 narcotic antagonist anti-alcohol-craving agents qh ah | |
+YV6.6.2e serotonin uptake inhibitors qh ah |
ZT4.14.12e | . . phentolamine qh |
BT | +YD8.2 ADH antagonists qh ah | |
+YT8.8 antihypertensive agents qh ah | ||
+YV12.2e alpha-adrenergic receptor blockaders qh ah |
ZT4.14.14e | . . tolazoline qh |
BT | +YV12.2e alpha-adrenergic receptor blockaders qh ah |
ZT4.16e | . oxazole qh |
ZT4.16.2 | . . isoxazoles qh |
HN | Introduced 2000. |
ZT4.16.2.2 | . . . alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid qh |
HN | Introduced 2000. | |
ST | alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate | |
AMPA |
ZT4.16.4e | . . pemoline qh |
BT | +BT6.8.4 schedule IV CNS stimulants qh ah | |
+YW8e CNS stimulants qh ah |
ZT4.16.4.2e | . . . magnesium pemoline qh |
BT | +YP10.8.10 agents for cocaine-concurrent mental disorders qh ah | |
+YP10.8.10.6 agents for cocaine-related cognitive impairment qh ah | ||
+YW8e CNS stimulants qh ah |
ZT4.16.6e | . . trimethadione qh |
BT | +YW4.6e anticonvulsants qh ah |
ZT4.18e | . piperazine qh |
NT | ZT8.16.2.2e flupenthixol qh ah |
ZT4.18.2e | . . amperozide qh |
HN | Introduced 2000. | |
SN | A derivative of piperazine with effects on stress-induced orders. |
ZT4.18.4e | . . trazodone qh |
BT | +YP10.8.6 cocaine blockers qh ah | |
+YP10.8.10.2 agents for cocaine-concurrent depression qh ah | ||
+YV6.6.2e serotonin uptake inhibitors qh ah |
ZT4.20e | . piperidine qh |
NT | BF6e phencyclidine qh ah | |
ZT2.2 isonipecotic acid qh ah |
ZT4.20.2e | . . paroxetine qh |
HN | Introduced 2000. | |
BT | +YV6.6.2e serotonin uptake inhibitors qh ah |
ZT4.20.4e | . . penfluridol qh |
BT | +YW4.10.2e antipsychotic tranquilizers qh ah |
ZT4.20.6e | . . perhexiline qh |
BT | +YT8.14e calcium channel blockers qh ah |
ZT4.20.8e | . . piperidone qh |
NT | ZJ2.10.10.6.2.2e thalidomide qh ah |
ZT4.20.8.2e | . . . cycloheximide qh |
HN | Introduced 1995. | |
BT | +YQ4.14.6 antifungal antibiotics qh ah |
ZT4.20.8.4e | . . . glutethimide qh |
SN | A nonbarbiturate hypnotic used in the treatment of insomnia. Physical and psychological dependence on this drug have occurred. | |
ST | Doriden | |
BT | +BT6.4.4 schedule II CNS depressants qh ah | |
+YW4.8.4e nonbarbiturate sedative-hypnotics qh ah |
ZT4.22e | . pyran qh |
ZT4.22.2e | . . patulin qh |
BT | +YX2.12 mycotoxins qh ah | |
+YX4e carcinogens qh ah |
ZT4.24e | . pyrazole qh |
ZT4.24.2e | . . 4-methylpyrazole qh |
ZT4.24.4e | . . antipyrine qh |
BT | +YQ2.2 nonsteroidal anti-inflammatory drugs qh ah | |
+YR2.2 nonnarcotic analgesics qh ah |
ZT4.26e | . pyridine qh |
ZT4.26.2e | . . aminopyrine qh |
NT | BD2e nicotine qh ah |
ZT4.26.2.2e | . . . pyrilamine qh |
BT | +YV6.4.2e histamine H1 receptor blockaders qh ah |
ZT4.26.2.4e | . . . tripelennamine qh |
SN | An antihistamine that has recently come into use in combination with pentazocine as a substitute for heroin. | |
BT | +YV6.4.2e histamine H1 receptor blockaders qh ah |
ZT4.26.2.6e | . . . dihydropyridine qh |
NT | ZP18.4.4e nimodipine qh ah | |
BT | +YP4.6e alcohol withdrawal agents qh ah |
ZT4.26.2.6.2e | . . . . Bay K 8644 qh |
HN | Introduced 1995. | |
BT | +YT8.12e calcium channel agonists qh ah | |
+ZP18.4e nicotinic acid qh ah |
ZT4.26.2.6.4e | . . . . isradipine qh |
HN | Introduced 2000. | |
BT | +YT8.8 antihypertensive agents qh ah | |
+YT8.14e calcium channel blockers qh ah |
ZT4.26.2.6.6e | . . . . nitrendipine qh |
HN | Introduced 1995. | |
BT | +YT8.8 antihypertensive agents qh ah | |
+YT8.14e calcium channel blockers qh ah |
ZT4.26.2.8 | . . . isonicotinic acid qh |
HN | Introduced 1995. | |
NT | ZF6.6e isoniazid qh ah |
ZT4.26.2.10e | . . . nifedipine qh |
BT | +YP4.6e alcohol withdrawal agents qh ah | |
+YT8.14e calcium channel blockers qh ah |
ZT4.26.4e | . . pheniramine qh |
ZT4.26.4.2e | . . . brompheniramine qh |
ZT4.26.4.2.2e | . . . . zimelidine qh |
ST | zimeldine | |
BT | +YP4.8.2.2e serotonergic anti-alcohol-craving agents qh ah | |
+YV6.6.2e serotonin uptake inhibitors qh ah | ||
+YW6e antidepressants qh ah |
ZT4.26.4.2.2.2e | . . . . . norzimelidine qh |
BT | +YP4.8.2.2e serotonergic anti-alcohol-craving agents qh ah |
ZT4.26.6e | . . picoline qh |
ZT4.26.6.2e | . . . pyridoxal qh |
BT | +YB12e vitamin B complex qh ah | |
RT | YC16.14.6.14 pyridoxal kinase qh ah |
ZT4.26.6.2.2e | . . . . pyridoxal phosphate qh |
BT | +YD4e coenzymes qh ah |
ZT4.26.6.4e | . . . pyridoxamine qh |
BT | +YB12e vitamin B complex qh ah |
ZT4.26.8e | . . picolinic acid qh |
ZT4.26.10e | . . pyridinium compounds qh |
ZT4.26.10.2e | . . . paraquat qh |
BT | +YX10.4.2 herbicides qh ah |
ZT4.26.10.4e | . . . pyrithiamine qh |
BT | +YT4 antimetabolites qh ah |
ZT4.26.12e | . . pyrithioxin qh |
ST | pyritinol | |
BT | +YP4.6e alcohol withdrawal agents qh ah |
ZT4.28e | . pyrimidines qh |
ZT4.28.2e | . . buspirone qh |
SN | A nonbenzodiazepine anxiolytic. At present, it is regarded as having negligible dependence potential. See *+YW4.8 sedative-hypnotics* qh ah. | |
BT | +YP4.8.2.2e serotonergic anti-alcohol-craving agents qh ah | |
+YP4.8.12.8 agents for alcohol-concurrent anxiety qh ah | ||
+YW4.8e sedative-hypnotics qh ah | ||
+YW4.8.6e antianxiety tranquilizers qh ah |
ZT4.28.4e | . . pyrimethamine qh |
BT | +YQ4.10.4.2 antimalarials qh ah |
ZT4.28.6e | . . pyrimidinone qh |
ZT4.28.6.2e | . . . risperidone qh |
HN | Introduced 2000. | |
SN | A dopamine and serotonin antagonist; an antipsychotic agent. | |
BT | +YV6.6e serotonin antagonists qh ah | |
+YW4.10.2e antipsychotic tranquilizers qh ah |
ZT4.28.6.4e | . . . ritanserin qh |
HN | ETOH descriptor 1995. | |
BT | +YP4.8.2.10 neuropeptide anti-alcohol-craving agents qh ah | |
+YV6.6e serotonin antagonists qh ah |
ZT4.28.6.6e | . . . barbiturates qh |
SN | A group of central nervous system depressants that chemically are substituted derivatives of barbituric acid; examples are amobarbital, pentobarbital, and secobarbital. They are used as
antiepileptics, anesthetics, hypnotics (sleep-inducing), and, less commonly, as anxiolytics or antianxiety drugs. Acute and chronic use induces effects similar to alcohol.
Barbiturates have a narrow therapeutic-to-toxic dosage ratio and are often lethal in overdose. Barbiturates are associated with the full range of substance use disorders listed in ICD-10 (they are classed with F13). | |
NT | +YW4.8.2e barbiturate sedative-hypnotics qh ah | |
BT | +YP4.6e alcohol withdrawal agents qh ah | |
+YR4e anesthetics qh ah | ||
+YW4e CNS depressants qh ah | ||
+YW4.4e general anesthetics qh ah | ||
+YW4.6e anticonvulsants qh ah | ||
RT | +YW4.8e sedative-hypnotics qh ah |
ZT4.28.6.6.4e | . . . . amobarbital qh |
ST | Amytal | |
BT | +BT6.6.2 schedule III CNS depressants qh ah | |
+YW4.8.2.4 intermediate-acting barbiturates qh ah |
ZT4.28.6.6.6e | . . . . barbital qh |
ST | Veronal | |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YW4.8.2.2 long-acting barbiturates qh ah |
ZT4.28.6.6.8e | . . . . murexide qh |
ZT4.28.6.6.10e | . . . . pentobarbital qh |
SN | A short-acting, quick-onset barbiturate. | |
ST | pentobarbital sodium | |
BT | +BT6.4.4 schedule II CNS depressants qh ah | |
+BT6.6.2 schedule III CNS depressants qh ah | ||
+YP6.6.2 barbiturate withdrawal agents qh ah | ||
+YW4.8.2.6 short-acting barbiturates qh ah |
ZT4.28.6.6.12e | . . . . phenobarbital qh |
ST | Luminal | |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6e alcohol withdrawal agents qh ah | ||
+YP4.6.12 anti-alcohol-related-seizures agents qh ah | ||
+YP6.6.2 barbiturate withdrawal agents qh ah | ||
+YW4.8.2.2 long-acting barbiturates qh ah |
ZT4.28.6.6.14e | . . . . primidone qh |
ZT4.28.6.6.16e | . . . . secobarbital qh |
ST | secobarbital sodium | |
Seconal | ||
BT | +BT6.6.2 schedule III CNS depressants qh ah | |
+YW4.8.2.6 short-acting barbiturates qh ah |
ZT4.28.6.6.18e | . . . . thiobarbiturates qh |
ZT4.28.6.6.18.4e | . . . . . thiopental qh |
ST | Nembutal | |
Pentothal | ||
thiopental sodium | ||
BT | +YW4.8.2.6 short-acting barbiturates qh ah |
ZT4.28.6.8e | . . . uracil qh |
ZT4.28.6.8.2e | . . . . thiouracil qh |
BT | +YG34.6 thyroid antagonists qh ah | |
+YT4 antimetabolites qh ah |
ZT4.28.6.8.2.2e | . . . . . propylthiouracil qh |
BT | +YT4 antimetabolites qh ah |
ZT4.30e | . pyrrole qh |
ZT4.30.2e | . . porphyrins qh |
NT | +GR16 porphyrin disorder qh ah | |
BT | +YZ10 pigments and dyes qh ah |
ZT4.30.2.2e | . . . porphyrinogens qh |
BT | +YZ10 pigments and dyes qh ah |
ZT4.30.2.4e | . . . protoporphyrins qh |
BT | +YZ10 pigments and dyes qh ah |
ZT4.30.2.6e | . . . uroporphyrins qh |
BT | +YZ10 pigments and dyes qh ah |
ZT4.30.4e | . . bilirubin qh |
SN | A tetrapyrrole bile pigment derived from the metabolism of porphyrins. | |
BT | +YZ10 pigments and dyes qh ah | |
RT | +GR18 hyperbilirubinemia qh ah | |
HG12.8e liver function test qh ah |
ZT4.30.4.2e | . . . biliverdin qh |
BT | +YZ10 pigments and dyes qh ah |
ZT4.30.6e | . . urobilin qh |
BT | +YZ10 pigments and dyes qh ah |
ZT4.30.8e | . . urobilinogen qh |
BT | +YZ10 pigments and dyes qh ah | |
RT | HG12.8e liver function test qh ah |
ZT4.30.10e | . . porphobilinogen qh |
ZT4.30.12e | . . tolmetin qh |
BT | +YQ2.2 nonsteroidal anti-inflammatory drugs qh ah | |
+YR2.2 nonnarcotic analgesics qh ah |
ZT4.32e | . pyrrolidine qh |
ZT4.32.2e | . . dipyrrolidine qh |
ZT4.32.2.2e | . . . tremorine qh |
BT | +YV10.4 ganglionic stimulants qh ah |
ZT4.32.4e | . . kainate qh |
HN | Introduced 1995. | |
ST | kainic acid | |
BT | +YQ4.10 antiparasitic agents qh ah |
ZT4.32.6e | . . pyrrolidinone qh |
NT | ZN2.20.2.2.2e piracetam qh ah | |
ZN6.2e succinimide qh ah |
ZT4.32.6.2e | . . . oxotremorine qh |
BT | +YV10.4 ganglionic stimulants qh ah |
ZT4.34e | . thiazine qh |
ZT4.34.2e | . . piroxicam qh |
BT | +YQ2.2 nonsteroidal anti-inflammatory drugs qh ah | |
+YR2.2 nonnarcotic analgesics qh ah |
ZT4.36e | . thiazole qh |
ZT4.36.2e | . . famotidine qh |
HN | Introduced 1995. | |
BT | +YT10.8 antiulcer agents qh ah | |
+YV6.4.4e histamine H2 receptor blockaders qh ah |
ZT4.38e | . cimetidine qh |
BT | +YT10.8 antiulcer agents qh ah | |
+YT10.14 antisecretory agents qh ah | ||
+YV6.4.4e histamine H2 receptor blockaders qh ah |
ZT6 | 2-ring heterocyclic compounds qh |
ZT6.2e | . cocaethylene qh |
HN | Introduced 1995. | |
SN | Cocaethylene is a psychoactive ethyl homologue of cocaine and is formed exclusively during the coadministration of cocaine and alcohol. | |
ST | benzoylecgonine ethyl ester | |
BT | +BP6 alcohol and cocaine qh ah | |
RT | +EB10.12e ethanol metabolism qh ah |
ZT6.4e | . benzazepines qh |
ZT6.4.2e | . . benzodiazepines qh |
SN | One of a group of structurally related drugs used mainly as antianxiety drugs, sedative/hypnotics, muscle relaxants, and antiepileptics. Also known as minor tranquilizers (deprecated) and
anxiolytics.
Benzodiazepines are frequently misused in conjunction with alcohol or opioid dependence. See *AA2.6 multiple drug use* qh ah. | |
NT | +YP4.6.8e benzodiazepines for alcohol withdrawal qh ah | |
BT | +YP4.8.12.8 agents for alcohol-concurrent anxiety qh ah | |
RT | YK10e benzodiazepine receptors qh ah | |
+YW4e CNS depressants qh ah | ||
+YW4.8.6.2 benzodiazepine tranquilizers qh ah | ||
+ZJ2.6.10.2.2.2e GABA qh ah |
ZT6.4.2.2e | . . . alprazolam qh |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6.8e benzodiazepines for alcohol withdrawal qh ah | ||
+YP4.8.12.8 agents for alcohol-concurrent anxiety qh ah | ||
+YW4.8.6.2.2 short-acting benzodiazepines qh ah |
ZT6.4.2.4e | . . . RO 15-4513 qh |
ST | imidazobenzodiazepine |
ZT6.4.2.6e | . . . carbamazepin qh |
BT | +YP10.8.2 anti-cocaine-craving agents qh ah |
ZT6.4.2.8e | . . . benzodiazepinones qh |
ZT6.4.2.8.2e | . . . . anthramycin qh |
ZT6.4.2.8.4e | . . . . bromazepam qh |
NT | ZT6.4.2.8.30e temazepam qh ah | |
BT | +BT6.8.2 schedule IV CNS depressants qh ah |
ZT6.4.2.8.6e | . . . . camazepam qh |
BT | +BT6.8.2 schedule IV CNS depressants qh ah |
ZT6.4.2.8.8e | . . . . clonazepam qh |
ST | Klonopin | |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6.8e benzodiazepines for alcohol withdrawal qh ah |
ZT6.4.2.8.12e | . . . . diazepam qh |
ST | Valium | |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6.8e benzodiazepines for alcohol withdrawal qh ah | ||
+YP6.6.4 benzodiazepine withdrawal agents qh ah | ||
+YW4.8.6.2.4 long-acting benzodiazepines qh ah |
ZT6.4.2.8.12.2e | . . . . . demethyldiazepam qh |
ZT6.4.2.8.14e | . . . . flumazenil qh |
HN | Changed descriptor 1995; through 1995 also use "flumazepil." | |
ST | flumazepil | |
RO 15-1788 |
ZT6.4.2.8.16e | . . . . flunitrazepam qh |
ST | Rohypnol | |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YW4.8.6.2.2 short-acting benzodiazepines qh ah |
ZT6.4.2.8.18e | . . . . flurazepam qh |
ST | Dalmane | |
flurazepam hydrochloride | ||
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6.8e benzodiazepines for alcohol withdrawal qh ah | ||
+YW4.8.6.2.4 long-acting benzodiazepines qh ah |
ZT6.4.2.8.20e | . . . . lorazepam qh |
ST | Ativan | |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6.8e benzodiazepines for alcohol withdrawal qh ah | ||
+YW4.8.6.2.2 short-acting benzodiazepines qh ah |
ZT6.4.2.8.22e | . . . . nitrazepam qh |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YW4.8.6.2.2 short-acting benzodiazepines qh ah |
ZT6.4.2.8.24e | . . . . oxazepam qh |
ST | Serax | |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6.8e benzodiazepines for alcohol withdrawal qh ah | ||
+YW4.8.6.2.2 short-acting benzodiazepines qh ah |
ZT6.4.2.8.26e | . . . . pirenzepine qh |
ZT6.4.2.8.28e | . . . . prazepam qh |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6.8e benzodiazepines for alcohol withdrawal qh ah | ||
+YT6.2 central muscle relaxants qh ah | ||
+YW4.8.6.2.4 long-acting benzodiazepines qh ah |
ZT6.4.2.8.30e | . . . . temazepam qh |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6.8e benzodiazepines for alcohol withdrawal qh ah | ||
+YW4.8.6.2.2 short-acting benzodiazepines qh ah | ||
+ZT6.4.2.8.4e bromazepam qh ah |
ZT6.4.2.8.32e | . . . . halazepam qh |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6.8e benzodiazepines for alcohol withdrawal qh ah | ||
+YW4.8.6.2.2 short-acting benzodiazepines qh ah |
ZT6.4.2.8.34e | . . . . omeprazole qh |
BT | +YT10.8 antiulcer agents qh ah | |
+YT10.14 antisecretory agents qh ah |
ZT6.4.2.10e | . . . chlordiazepoxide qh |
SN | An antianxiety tranquilizer derived from benzodiazepine. | |
ST | chlordiazepoxide hydrochloride | |
Librium | ||
methaminodiazepoxide | ||
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6.8e benzodiazepines for alcohol withdrawal qh ah | ||
+YW4.8.6.2.4 long-acting benzodiazepines qh ah |
ZT6.4.2.10.2e | . . . . clorazepate qh |
ST | chlorazepate dipotassium | |
Tranxene | ||
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YP4.6.8e benzodiazepines for alcohol withdrawal qh ah | ||
+YW4.8.6.2.4 long-acting benzodiazepines qh ah |
ZT6.4.2.12e | . . . midazolam qh |
BT | +BT6.8.2 schedule IV CNS depressants qh ah |
ZT6.4.2.14e | . . . triazolam qh |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YW4.8.4e nonbarbiturate sedative-hypnotics qh ah | ||
+YW4.8.6.2.2 short-acting benzodiazepines qh ah |
ZT6.4.4e | . . diltiazem qh |
ZT6.6e | . benzimidazoles qh |
ZT6.6.2e | . . pimozide qh |
BT | +YW4.10.2e antipsychotic tranquilizers qh ah |
ZT6.8e | . benzopyrans qh |
ZT6.8.2e | . . chroman qh |
NT | BJ4.2e catechin qh ah |
ZT6.8.2.2 | . . . flavones qh |
BT | +YB8e flavonoids qh ah | |
RT | +YZ10 pigments and dyes qh ah |
ZT6.8.2.2.2e | . . . . isoflavonoids qh |
HN | Introduced 2000. | |
ST | isoflavones |
ZT6.8.2.2.2.2e | . . . . . daidzin qh |
HN | Introduced 2000. | |
SN | Extracted from plant Pueraria lobata or kudzu root (radix puerariae). | |
ST | daidzein | |
BT | +YP4.2e anti-alcohol-intoxication agents qh ah | |
+YP4.8.2e anti-alcohol-craving agents qh ah |
ZT6.8.2.2.2.4e | . . . . . puerarin qh |
HN | Introduced 2000. | |
SN | Extracted from plant Pueraria lobata or kudzu root (radix puerariae). | |
BT | +YP4.2e anti-alcohol-intoxication agents qh ah | |
+YP4.8.2e anti-alcohol-craving agents qh ah |
ZT6.8.4e | . . coumarin qh |
HN | ETOH descriptor 1995. |
ZT6.8.4.2e | . . . 4-hydroxycoumarin qh |
ZT6.8.4.2.2e | . . . . warfarin qh |
BT | +YX10.4.8 rodenticides qh ah |
ZT6.10e | . indoles qh |
NT | ZP10e ibogaine qh ah |
ZT6.10.2e | . . hydroxytryptophol qh |
HN | Introduced 2000. |
ZT6.10.2.2e | . . . 5-hydroxytryptophol qh |
HN | Introduced 2000. | |
ST | 5-HTOL | |
BT | +HB4.6.2.8.2 alcohol-related biochemical markers qh ah |
ZT6.10.4e | . . indoleacetic acid qh |
HN | Introduced 1995. | |
BT | +ZT2 heterocyclic acid qh ah |
ZT6.10.4.2e | . . . hydroxyindoleacetic acid qh |
HN | Introduced 1995. | |
ST | 5-HIAA | |
5-hydroxyindoleacetic acid | ||
HIAA |
ZT6.10.6e | . . indomethacin qh |
BT | +YQ2.2 nonsteroidal anti-inflammatory drugs qh ah | |
+YR2.2.6 gout suppressants qh ah |
ZT6.10.8e | . . oxyphenisatin qh |
ZT6.10.10e | . . melanin qh |
BT | +YZ10 pigments and dyes qh ah | |
RT | XH2.2.2e melanocyte qh ah | |
+ZN2.8.4e dopa qh ah |
ZT6.10.12e | . . tryptamine qh |
SN | Nonhallucinogenic chemical from which the hallucinogenic drugs dimethyltryptamine (DMT), LSD, and psilocybin can be derived. | |
NT | BF8.4 psilocybine qh ah | |
YH2.2.2e melatonin qh ah | ||
BT | +ZN2.18.2.2e biogenic monoamines qh ah |
ZT6.10.12.2e | . . . N,N-Dimethyltryptamine qh |
HN | Introduced 2000. | |
SN | An N-methylated indoleamine derivative, a serotonergic hallucinogen found in several plants, especially Prestonia amazonica (Apocynaceae) and in mammalian brain, blood, and urine. It apparently acts as an agonist at some types of serotonin receptors and an antagonist at others. | |
ST | 3-(2-(Dimethylamino)ethyl)indole | |
BT | +YV6.6e serotonin antagonists qh ah |
ZT6.10.12.4e | . . . serotonin qh |
ST | 5-HT | |
5-hydroxytryptamine | ||
hydroxytryptamine | ||
BT | +YJ2e neurotransmitters qh ah | |
+YJ2.4e monoamine neurotransmitters qh ah | ||
+YM14 slow-reacting substances qh ah | ||
+YV4 neuroregulators qh ah | ||
+ZN2e amines qh ah | ||
RT | YK6.10.4e serotonin receptors qh ah | |
+YL6e antagonists qh ah | ||
+YV6.6e serotonin antagonists qh ah |
ZT6.12e | . isoquinolines qh |
NT | ZP2e bicuculline qh ah | |
+ZP24e salsoline alkaloids qh ah | ||
+ZQ12.2e papaverine qh ah | ||
RT | +ZG2.4e acetaldehyde qh ah |
ZT6.12.2e | . . emetine qh |
BT | +YP4.8.10e conditioned alcohol aversion agents qh ah | |
RT | +HK2.12.2e chemical aversion therapy qh ah |
ZT6.12.6e | . . nomifensine qh |
BT | +YV4.2 dopaminergic agents qh ah | |
+YW6e antidepressants qh ah |
ZT6.12.8e | . . beta-carboline qh |
ZT6.14e | . penicillinic acid qh |
ZT6.16e | . pteridine qh |
ZT6.18e | . purines qh |
ZT6.18.2e | . . purinone qh |
ZT6.18.2.2e | . . . xanthines qh |
NT | +ZP28e xanthine alkaloids qh ah | |
BT | +YW8e CNS stimulants qh ah | |
RT | YC14.12.4e xanthine dehydrogenase qh ah | |
YC14.12.6e xanthine oxidase qh ah |
ZT6.18.4e | . . flavins qh |
NT | YB12.20e riboflavin qh ah | |
BT | +YZ10 pigments and dyes qh ah | |
RT | +YB8e flavonoids qh ah |
ZT6.18.4.2e | . . . uric acid qh |
ZT6.20e | . quinazolines qh |
ZT6.20.2e | . . ketanserin qh |
BT | +YT14.6 platelet aggregation inhibitors qh ah | |
+YV6.6e serotonin antagonists qh ah |
ZT6.20.4e | . . methaqualone qh |
SN | Nonbarbiturate sedative-hypnotic that produces sleep for about 6 to 8 hours, originally marketed as an alternative to barbiturates. When taken in large doses for purposes other than sleep inducement, it produces muscular relaxation, feelings of contentment, and total passivity, a state somewhat resembling drunkenness. | |
ST | Quaalude | |
BT | +BT6.2.4 schedule I CNS depressants qh ah | |
+YW4.8.4e nonbarbiturate sedative-hypnotics qh ah |
ZT6.20.6e | . . prazosin qh |
BT | +YT8.8 antihypertensive agents qh ah | |
+YV12.2e alpha-adrenergic receptor blockaders qh ah |
ZT6.22e | . quinolines qh |
NT | ZP4.2e quinidine qh ah | |
ZP4.4e quinine qh ah |
ZT6.22.2e | . . quipazines qh |
ZT6.24e | . quinolones qh |
HN | Introduced 2000. |
ZT6.24.2e | . . ciprofloxacin qh |
HN | Introduced 2000. | |
BT | +YQ4.6 antibacterial agents qh ah |
ZT8 | 3-ring heterocyclic compounds qh |
ZT8.2e | . acridines qh |
ZT8.2.2e | . . aminoacridine qh |
ZT8.2.2.2e | . . . quinacrine qh |
BT | +YD8.2 ADH antagonists qh ah | |
+YQ4.10.4.2 antimalarials qh ah | ||
+YQ6 antineoplastic agents qh ah |
ZT8.2.2.4e | . . . imipramine qh |
ST | imipramine hydrochloride | |
BT | +YP4.8.12.6 agents for alcohol-concurrent depression qh ah | |
+YP4.8.12.8 agents for alcohol-concurrent anxiety qh ah | ||
+YP10.8.6 cocaine blockers qh ah | ||
+YP10.8.10.2 agents for cocaine-concurrent depression qh ah | ||
+YW6.2 tricyclic antidepressants qh ah |
ZT8.2.2.6e | . . . desipramine qh |
ST | desmethylimipramine | |
BT | +YP4.8.12.6 agents for alcohol-concurrent depression qh ah | |
+YP10.8.2 anti-cocaine-craving agents qh ah | ||
+YP10.8.10.2 agents for cocaine-concurrent depression qh ah | ||
+YP10.8.10.4 agents for cocaine-concurrent anxiety qh ah | ||
+YW6.2 tricyclic antidepressants qh ah |
ZT8.2.2.8e | . . . trimipramine qh |
ZT8.4e | . dibenzazepines qh |
ZT8.4.2e | . . carbamazepine qh |
ST | Depakene | |
Depakote | ||
Tegretol | ||
BT | +YP4.6e alcohol withdrawal agents qh ah | |
+YP4.6.12 anti-alcohol-related-seizures agents qh ah | ||
+YP10.8 cocaine relapse prevention agents qh ah |
ZT8.4.2.2e | . . . clozapine qh |
HN | Introduced 2000. | |
BT | +YV6.6e serotonin antagonists qh ah | |
+YW4.10.2e antipsychotic tranquilizers qh ah |
ZT8.4.2.4e | . . . clomipramine qh |
HN | Introduced 2000. |
ZT8.6e | . dibenzoxazepines qh |
HN | Introduced 2000. |
ZT8.6.2e | . . loxapine qh |
HN | Introduced 2000. |
ZT8.6.2.2e | . . . amoxapine qh |
HN | Introduced 2000. | |
BT | +YV6.6.2e serotonin uptake inhibitors qh ah |
ZT8.8e | . dibenzoxepins qh |
ZT8.8.2e | . . doxepin qh |
BT | +YP4.8.12.6 agents for alcohol-concurrent depression qh ah | |
+YP10.8.10.2 agents for cocaine-concurrent depression qh ah | ||
+YW4.8.6e antianxiety tranquilizers qh ah |
ZT8.8.4e | . . harmine qh |
BT | +YW10e hallucinogens qh ah | |
+ZPe alkaloids qh ah |
ZT8.10e | . phenanthroline qh |
ZT8.12e | . phenazine qh |
ZT8.12.2e | . . thiothixene qh |
BT | +YW4.10.2e antipsychotic tranquilizers qh ah |
ZT8.14e | . phenothiazine qh |
ZT8.14.2e | . . chlorpromazine qh |
HN | Introduced 1995. | |
ST | Thorazine | |
BT | +YW4.10.2.4 phenothiazine tranquilizers qh ah |
ZT8.14.4e | . . perphenazine qh |
BT | +YW4.10.2.4 phenothiazine tranquilizers qh ah |
ZT8.14.6e | . . prochlorperazine qh |
BT | +YW4.10.2.4 phenothiazine tranquilizers qh ah |
ZT8.14.8e | . . promazine qh |
BT | +YW4.10.2.4 phenothiazine tranquilizers qh ah |
ZT8.14.10e | . . promethazine qh |
ST | promethazine hydrochloride | |
BT | +YV6.2 antiemetics qh ah | |
+YV6.4.2e histamine H1 receptor blockaders qh ah | ||
+ZN2.4e propylamine qh ah |
ZT8.14.12e | . . thioridazine qh |
BT | +YP4.8.12.2 dopaminergic blockers for alcohol-concurrent mental disorders qh ah | |
+YW4.10.2.4 phenothiazine tranquilizers qh ah |
ZT8.14.14e | . . trifluoperazine qh |
BT | +YW4.10.2.4 phenothiazine tranquilizers qh ah |
ZT8.16e | . xanthene qh |
ZT8.16.2e | . . thioxanthene qh |
ZT8.16.2.2e | . . . flupenthixol qh |
BT | +YP10.8 cocaine relapse prevention agents qh ah | |
+YP10.8.2 anti-cocaine-craving agents qh ah | ||
+YW4.10.2e antipsychotic tranquilizers qh ah | ||
+ZT4.18e piperazine qh ah |
ZT10 | 4 or more ring heterocyclic compounds qh |
ST | 4-ring or more heterocyclic compounds | |
NT | +ZQ4 phenanthrene derivative opioids qh ah | |
RT | +ZP8 ergot alkaloids qh ah |
ZT10.2e | . yohimban qh |
NT | ZP26.2e reserpine qh ah | |
ZP26.4e yohimbine qh ah | ||
RT | +ZP26e rauwolfia alkaloids qh ah |
ZT12 | bridged-ring heterocyclic compounds qh |
NT | ZQ4.6.4e naloxone qh ah | |
ZQ4.6.6e naltrexone qh ah |
ZT12.2e | . quinuclidine qh |
NT | ZJ2.10.4.4.2e quinuclidinyl benzilate qh ah |
classification thesaurus glossary dictionary definition subject heading list ontology vocabulary knowledge structure knowledge organization terminology concept